Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HTRA1 | Q92743 | 1/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6465932 | 1.00 | USP2 (0.40) | USP2SMN1; SMN2RECQLHSD17B10CHRM2 | |
| SCHEMBL6466005 | 0.88 | SMN1; SMN2 (0.38) | USP2SMN1; SMN2RECQLHSD17B10CHRM2 | |
| SCHEMBL1024057 | 0.85 | HSD17B10 (0.43) | USP2SMN1; SMN2RECQLHSD17B10CHRM2 | |
| SCHEMBL17031907 | 0.85 | USP2 (0.41) | USP2SMN1; SMN2RECQLHSD17B10CHRM2 | |
| SCHEMBL6448272 | 0.85 | HSD17B10 (0.43) | USP2SMN1; SMN2RECQLHSD17B10CHRM2 | |
| SCHEMBL3511572 | 0.84 | SMN1; SMN2 (0.49) | USP2SMN1; SMN2RECQLHSD17B10NR1H2 | |
| SCHEMBL16604796 | 0.84 | SMN1; SMN2 (0.49) | USP2SMN1; SMN2RECQLHSD17B10NR1H2 | |
| SCHEMBL16604806 | 0.84 | SMN1; SMN2 (0.49) | USP2SMN1; SMN2RECQLHSD17B10NR1H2 | |
| SCHEMBL8892617 | 0.83 | PTPN1 (0.41) | USP2SMN1; SMN2RECQLHSD17B10CHRM2 | |
| SCHEMBL31716576 | 0.83 | PTPN1 (0.41) | USP2SMN1; SMN2RECQLHSD17B10CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110118305-A1 | COMPOUNDS | SANOFI-AVENTIS (FR) | 2011-05-19 | — | — | US | disclosed |
| EP-1517907-B1 | AZABICYCLO-OCTANE AND NONANE DERIVATIVES WITH DDP-IV INHIBITING ACTIVITY | SANOFI AVENTIS (FR) | 2011-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118305-A1 | COMPOUNDS | DPP4, DPP3, DPP8 | USP2 1253/4885SMN1; SMN2 4066/4885RECQL 3436/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.